A Polygenic Risk Score Assessment Reveals More Screening Participants with Clinically Significant Prostate Cancer Than Those Who Would Be Identified with PSA or MRI By Ogkologos - April 30, 2025 771 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the BARCODE1 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR How Alcohol Increases Your Cancer Risk and What to Know About... August 29, 2023 EMA Recommends Extension of Therapeutic Indications for Rucaparib October 27, 2023 Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell... July 15, 2025 How can we diagnose more cancers earlier? July 27, 2021 Load more HOT NEWS FDA Grants Accelerated Approval to Melphalan Flufenamide for Relapsed or Refractory... ΚΑΡΚΙΝΟΣ ΘΥΡΕΟΕΙΔΟΥΣ ΑΔΕΝΑ No EFS Benefit From Adding Atezolizumab To 1-Year BCG Therapy In... FDA Grants Accelerated Approval to Adagrasib with Cetuximab for KRAS G12C-mutated...
